Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive

The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 55; no. 1; pp. 58 - 67
Main Authors Boursier, Jérôme, de Ledinghen, Victor, Zarski, Jean-Pierre, Fouchard-Hubert, Isabelle, Gallois, Yves, Oberti, Frédéric, Calès, Paul
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2012
Wiley
Wolters Kluwer Health, Inc
Wiley-Blackwell
Subjects
Online AccessGet full text
ISSN0270-9139
1527-3350
1527-3350
DOI10.1002/hep.24654

Cover

More Information
Summary:The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 (“successive algorithms”). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10−3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10−3). Similarly, successive BA had significantly (P ≤ 10−3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10−3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58–67)
Bibliography:Program Hospitalier de Recherche Clinique (PHRC)
Potential conflict of interest: P.C., I.F.H., and F.O. have stock ownership in BioLiveScale Inc., which has a license for FibroMeter from the University of Angers.
FIBROSTAR HC/EP23
French Department of Health in 1994 and 2002 for SNIFF 32
Agence National de Recherche sur le Sida et les Hépatites (ANRS)
Supported by the Program Hospitalier de Recherche Clinique (PHRC) of the French Department of Health in 1994 and 2002 for SNIFF 32 and the Agence National de Recherche sur le Sida et les Hépatites (ANRS) for FIBROSTAR HC/EP23.
istex:0A54D214C6902F0B45226975325AF12159FFE6B6
ArticleID:HEP24654
ark:/67375/WNG-33H4V04Q-J
fax: (33) 2 41 35 41 19
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Undefined-3
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.24654